Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epitope-specific tolerance induction with an engineered immunoglobulin

E T Zambidis1, D W Scott

  • 1Department of Immunology, Holland Laboratory, American Red Cross, Rockville, MD 20855, USA.

Proceedings of the National Academy of Sciences of the United States of America
|May 14, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades.

British journal of haematology·2025
Same author

Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.

British journal of haematology·2024
Same author

Pleuro-Pneumonia, with Subsequent Scorbutus.

Atlanta medical and surgical journal·2022
Same author

Letter to the Editor.

Veterinary dermatology·2021
Same author

10<sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

mAbs·2020
Same author

Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.

Current oncology (Toronto, Ont.)·2019

Engineered IgG fusion proteins can induce immune tolerance to specific epitopes. This "genetic hapten-carrier" system offers a novel approach to tailor immune responses for therapeutic applications.

Area of Science:

  • Immunology
  • Protein Engineering

Background:

  • Immunoglobulins (IgG) are effective tolerogenic carriers, inducing unresponsiveness by leveraging their long half-life and ability to crosslink receptors.
  • Previous studies utilized IgG as a carrier for haptens and peptides, demonstrating its potential in immune modulation.

Purpose of the Study:

  • To engineer a novel "genetic hapten-carrier" system using mouse IgG1 fused with a defined epitope.
  • To evaluate the in vivo feasibility of engineered tolerogens for modulating immune responses to specific epitopes.

Main Methods:

  • Engineered a fusion protein of mouse IgG1 with the 12-26 epitope from bacteriophage lambda cI repressor protein.
  • Developed an experimental system using recombinant flagellin and murine IgG1 tolerogen, both expressing the target epitope.
  • Administered peptide-grafted IgG molecules intravenously or via transfected autologous B cells.

Related Experiment Videos

Main Results:

  • Peptide-grafted IgG molecules efficiently modulated cellular and humoral immune responses.
  • Both intravenous injection and expression by transfected B cells proved effective in inducing tolerance.
  • Demonstrated the ability to control immune responses towards specific epitopes.

Conclusions:

  • Engineered IgG fusion proteins represent a feasible strategy for inducing immune tolerance.
  • This "tailor-design" approach allows for precise control over immune responses, directing them towards tolerance or immunity.
  • The developed system provides a versatile platform for designing targeted immunotherapies.